Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

20222,480 citationsJournal Articlebronze Open Access

Authors

Scott D. Solomon · Brigham and Women's Hospital

John J.V. McMurray · British Heart Foundation

Brian Claggett · Brigham and Women's Hospital

Rudolf A. de Boer · University Medical Center Groningen

David L. DeMets · University of Wisconsin–Madison

Adrian F. Hernandez · British Heart Foundation

Silvio E. Inzucchi

Abstract

Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).

Topics & Keywords

Diabetes Treatment and Management Heart Failure Treatment and Management Pancreatic function and diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 387, Issue 12, pp. 1089-1098

DOI: 10.1056/nejmoa2206286

Field-Weighted Citation Impact: 320.72